Pacific Biosciences of California (PACB) stock up but underperforms market, negative.

From Nasdaq: 2025-03-14 18:15:07

Pacific Biosciences of California (PACB) closed at $1.22, up 1.67% from the previous day. Stock performance fell 18.92% in the last month. Earnings forecast a 26.92% increase at -$0.19 EPS, with revenue expected to decline by 12.13% to $34.1 million. Zacks Rank rates PACB as #3 (Hold).

The Medical – Instruments industry, part of the Medical sector, ranks in the top 33% of all industries. Zacks Industry Rank of 81 indicates industry strength. Zacks research shows top 50% rated industries outperform the bottom half by 2 to 1. Stay updated with Zacks.com for stock-impacting metrics.

Zacks Research Chief names “Stock Most Likely to Double,” highlighting 5 stocks with potential gains of 100% or more. Director of Research Sheraz Mian selects an innovative financial firm with a fast-growing customer base and cutting-edge solutions. Zacks’ top picks have a history of significant gains, with this stock poised for big growth.



Read more at Nasdaq: Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know